Glucagon receptor is required for long-term survival: A natural history study of the Mahvash disease in a murine model

Endocrinologia y Nutricion

Volumn 59, Issue 9, 2012, Pages 523-530

  Yu, Run ^a   Ren, Song Guang ^a   Mirocha, James ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Glucagon receptor; Mahvash disease; Murine model; Pancreatic neuroendocrine tumors

Indexed keywords

GLUCAGON RECEPTOR; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CACHEXIA; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH; HETEROZYGOSITY; HISTOPATHOLOGY; HISTORY; HYPERGLUCAGONEMIA; LETHARGY; LONG TERM SURVIVAL; MAHVASH DISEASE; MALE; METASTASIS; MORTALITY; MOUSE; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; RARE DISEASE; SURVIVAL RATE;

ANIMALS; BLOOD GLUCOSE; CACHEXIA; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GLUCAGON; HUMANS; HYPOGLYCEMIA; LETHARGY; LIVER NEOPLASMS; LONGEVITY; MALE; MICE; MICE, INBRED DBA; MICE, KNOCKOUT; NEOPLASTIC SYNDROMES, HEREDITARY; NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL; PANCREATIC NEOPLASMS; RECEPTORS, GLUCAGON; SKIN NEOPLASMS;

EID: 84868638057     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2012.06.006     Document Type: Article

References (22)

1. Yu R., Nissen N.N., Dhall D., Heaney A.P. Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas. Pancreas 2008, 36:428-431.
2. Zhou C., Dhall D., Nissen N.N., Chen C.R., Yu R. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas 2009, 38:941-946.
3. Ouyang D., Dhall D., Yu R. Pathologic pancreatic endocrine cell hyperplasia. World J Gastroenterol 2011, 17:137-143.
4. Yu R., Wawrowsky K., Zhou C. A natural inactivating mutant of human glucagon receptor exhibits multiple abnormalities in processing and signaling. Endocrinol Nutr 2011, 58:258-266.
5. Henopp T., Anlauf M., Schmitt A., Schlenger R., Zalatnai A., Couvelard A., et al. Glucagon cell adenomatosis: a newly recognized disease of the endocrine pancreas. J Clin Endocrinol Metab 2009, 94:213-217.
6. Otto A.I., Marschalko M., Zalatnai A., Toth M., Kovacs J., Harsing J., et al. Glucagon cell adenomatosis: a new entity associated with necrolytic migratory erythema and glucagonoma syndrome. J Am Acad Dermatol 2011, 65:458-459.
7. Anlauf M., Schlenger R., Perren A., Bauersfeld J., Koch C.A., Dralle H., et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 2006, 30:560-574.
8. Corcos O., Couvelard A., Giraud S., Vullierme M.P., Dermot O'Toole, Rebours V., et al. Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological and genetic features. Pancreas 2008, 37:85-93.
9. Parker J.C., Andrews K.M., Allen M.R., Stock J.L., McNeish J.D. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 2002, 290:839-843.
10. Yu R., Dhall D., Nissen N.N., Zhou C., Ren S.G. Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice. PLoS One 2011, 6:e23397.
11. Conarello S.L., Jiang G., Mu J., Li Z., Woods J., Zycband E., et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 2007, 50:142-150.
12. Vuguin P.M., Kedees M.H., Cui L., Guz Y., Gelling R.W., Nejathaim M., et al. Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. Endocrinology 2006, 147:3995-4006.
13. Ouhilal S., Vuguin P., Cui L., Du X.Q., Gelling R.W., Reznik S.E., et al. Hypoglycemia, hyperglucagonemia, and fetoplacental defects in glucagon receptor knockout mice: a role for glucagon action in pregnancy maintenance. Am J Physiol Endocrinol Metab 2012, 302:E522-E531.
14. Umino Y., Everhart D., Solessio E., Cusato K., Pan J.C., Nguyen T.H., et al. Hypoglycemia leads to age-related loss of vision. Proc Natl Acad Sci U S A 2006, 103:19541-19545.
15. Longuet C., Sinclair E.M., Maida A., Baggio L.L., Maziarz M., Charron M.J., et al. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab 2008, 8:359-371.
16. Yang J., MacDougall M.L., McDowell M.T., Xi L., Wei R., Zavadoski W.J., et al. Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes. BMC Genomics 2011, 12:281.
17. Berglund E.D., Lustig D.G., Baheza R.A., Hasenour C.M., Lee-Young R.S., Donahue E.P., et al. Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver. Diabetes 2011, 60:2720-2729.
18. Verbeke C.S. Endocrine tumours of the pancreas. Histopathology 2010, 56:669-682.
19. Schimmack S., Svejda B., Lawrence B., Kidd M., Modlin I.M. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 2011, 396:273-298.
20. Lu J., Herrera P.L., Carreira C., Bonnavion R., Seigne C., Calender A., et al. Alpha cell-specific Men1 ablation triggers the transdifferentiation of glucagon-expressing cells and insulinoma development. Gastroenterology 2010, 138:1954-1965.
21. Unger R.H., Cherrington A.D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012, 122:4-12.
22. Bagger J.I., Knop F.K., Holst J.J., Vilsbøll T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes Metab 2011, 13:965-971.